Strides Pharma Science Ltd Sees Technical Momentum Shift Amid Strong Returns

Price Momentum and Moving Averages

Strides Pharma’s current price of ₹1,198.25 is approaching its 52-week high of ₹1,231.45, indicating strong upward momentum over the past year. The daily moving averages remain bullish, reinforcing the short-term positive trend. This is a critical factor for traders who rely on moving averages as dynamic support levels, signalling that the stock is maintaining its upward trajectory despite minor pullbacks. The daily moving average alignment suggests that the stock is well-positioned to test resistance levels near its recent highs.

MACD and Momentum Oscillators

The Moving Average Convergence Divergence (MACD) indicator presents a mixed picture. On a weekly basis, the MACD is mildly bearish, indicating some short-term weakening in momentum. However, the monthly MACD remains bullish, suggesting that the longer-term trend continues to favour the bulls. This divergence between weekly and monthly MACD readings highlights a potential consolidation phase, where short-term profit-taking may occur without derailing the broader uptrend.

Relative Strength Index (RSI) Signals

The RSI readings further complicate the technical outlook. The weekly RSI currently shows no definitive signal, hovering in a neutral zone that neither indicates overbought nor oversold conditions. Conversely, the monthly RSI is bearish, implying that the stock may be experiencing some underlying weakness or a potential correction in the medium term. Investors should watch for any RSI movement below 40 on the monthly chart, which could signal a deeper retracement.

Bollinger Bands and Volatility

Bollinger Bands on both weekly and monthly charts remain bullish, suggesting that volatility is contained within an upward trending channel. The stock price’s recent high of ₹1,217.00 and low of ₹1,182.60 today indicate a relatively tight trading range, consistent with a controlled bullish momentum. This pattern often precedes a breakout, either to the upside or downside, making it essential for traders to monitor volume and price action closely.

Other Technical Indicators: KST, Dow Theory, and OBV

The Know Sure Thing (KST) oscillator is mildly bearish on both weekly and monthly timeframes, signalling a cautious stance on momentum sustainability. Meanwhile, Dow Theory assessments are mildly bullish weekly but mildly bearish monthly, reflecting a transitional phase in market sentiment. On a positive note, the On-Balance Volume (OBV) indicator is bullish across both weekly and monthly charts, indicating that buying volume is supporting the price advances. This divergence between price momentum and volume suggests accumulation by informed investors despite short-term technical hesitations.

Comparative Returns and Market Context

Strides Pharma Science Ltd has outperformed the broader Sensex index significantly across multiple time horizons. Over the past week, the stock returned 14.41%, while the Sensex declined by 2.36%. This outperformance extends to longer periods, with the stock delivering 18.99% over one month compared to the Sensex’s -4.76%, and a year-to-date return of 32.79% against the Sensex’s -12.27%. Over one year, the stock’s return stands at 36.34%, dwarfing the Sensex’s -7.81% loss.

Longer-term performance is even more striking. Over three years, Strides Pharma has surged 444.49%, vastly outperforming the Sensex’s 12.26% gain. Similarly, five-year returns of 339.42% and ten-year returns of 187.52% underscore the company’s robust growth trajectory relative to the benchmark’s 28.23% and 159.62%, respectively. This exceptional relative strength supports the technical bullishness observed in the stock’s price action and momentum indicators.

Mojo Score Upgrade and Market Capitalisation

Reflecting these positive developments, Strides Pharma’s Mojo Score has improved to 71.0, earning a Buy grade as of 8 September 2026, upgraded from a previous Hold rating. This upgrade signals increased confidence in the stock’s fundamentals and technical outlook. The company is classified as a small-cap within the Pharmaceuticals & Biotechnology sector, which often offers higher growth potential albeit with increased volatility. The recent technical shifts align well with this growth profile, suggesting that investors may benefit from the stock’s momentum while managing risk prudently.

Technical Trend Summary and Outlook

The overall technical trend for Strides Pharma has shifted from bullish to mildly bullish, reflecting a more cautious but still positive stance. The mixed signals from MACD, RSI, and KST oscillators indicate that while short-term momentum may face some headwinds, the longer-term trend remains intact. The bullish moving averages and OBV readings provide a solid foundation for potential further gains, especially if the stock can break decisively above recent highs near ₹1,231.45.

Investors should monitor key support levels around ₹1,180 and watch for confirmation from momentum indicators such as a weekly MACD crossover or RSI improvement. A sustained move above the upper Bollinger Band on monthly charts could signal renewed strength and a possible acceleration in the uptrend. Conversely, deterioration in volume or a drop below moving averages would warrant caution.

Conclusion: Balanced Technical Signals Point to Cautious Optimism

Strides Pharma Science Ltd’s technical indicators present a complex but encouraging picture. While some oscillators suggest mild bearishness or neutral momentum in the short term, the prevailing trend remains mildly bullish, supported by strong moving averages and volume patterns. The stock’s impressive relative returns compared to the Sensex reinforce the fundamental strength underpinning this technical setup.

For investors, the current environment calls for a balanced approach: recognising the potential for further upside while remaining vigilant for signs of momentum weakening. The recent Mojo Score upgrade to Buy reflects this positive sentiment, signalling that Strides Pharma is well-positioned within the Pharmaceuticals & Biotechnology sector for continued growth. Monitoring key technical levels and momentum indicators will be essential to capitalise on this evolving opportunity.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →